|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received April 17, 2002
Accepted after revision May 15, 2002
1 Veterans Affairs Medical Center, Cardiology Division, 111C, 4150 Clement Street, San Francisco, CA 94121, USA
2 Centre for Immunology, St. Vincent's Hospital, Sydney, NSW, 2010, Australia
3 Biomedical Systems Research Group, Division of Information and Communication Sciences, Macquarie University, NSW, 2109, Australia.
* To whom correspondence should be addressed. E-mail: lynnet3{at}itsa.ucsf.edu.
Inotropic agents that increase the intracellular levels of cAMP have been shown to increase crossbridge turnover kinetics in intact rat ventricular muscle, as measured by the parameter fmin (the frequency at which dynamic stiffness is minimum). These agents are also known to increase the level of phosphorylation of two candidate myofibrillar proteins: myosin binding protein C (MyBPC) and Troponin I (TnI), but have no effect on myosin light chain 2 phosphorylation (MyLC2). The aim of this study was to investigate whether the phosphorylation of TnI and/or MyBPC was responsible for the increase in crossbridge cycling kinetics (as captured by fmin) seen with the elevation of cAMP within cardiac tissue. Using barium-activated intact rat papillary muscle, we investigated the actions of isobutylmethylxanthine (IBMX), an inhibitor of cAMP- dependent phosphatase, which simulates the action of ß-adrenergic agents, and the chemical phosphatase 2,3-butanedione monoxime (BDM), which has been shown to dephosphorylate a number of contractile proteins. The presence of 0.6 mM IBMX approximately doubled the fmin value of intact rat papillary muscle. This action was unaffected by the addition of BDM. In the presence of IBMX and BDM, the level of phosphorylation of MyBPC was unchanged, that of MyLC2 was reduced to 60 % of control, yet that of TnI was markedly increased (to 30 % above control levels). We conclude that TnI phosphorylation, mediated by cAMP-dependent protein kinase A, is the molecular basis for the enhanced crossbridge cycling seen during ß-adrenergic stimulation of the heart.
This article has been cited by other articles:
![]() |
S. Sadayappan, N. Finley, J. W. Howarth, H. Osinska, R. Klevitsky, J. N. Lorenz, P. R. Rosevear, and J. Robbins Role of the acidic N' region of cardiac troponin I in regulating myocardial function FASEB J, April 1, 2008; 22(4): 1246 - 1257. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Stelzer, J. R. Patel, and R. L. Moss Acceleration of Stretch Activation in Murine Myocardium due to Phosphorylation of Myosin Regulatory Light Chain J. Gen. Physiol., August 28, 2006; 128(3): 261 - 272. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Caruso, J. Hamill, M. Yamauchi, D. Mercado, T. Cook, B. Higginson, S. O'Meara, J. Elias, and S. Siconolfi Albuterol aids resistance exercise in reducing unloading-induced ankle extensor strength losses J Appl Physiol, May 1, 2005; 98(5): 1705 - 1711. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Kirton, A. J. Taberner, P. M. F. Nielsen, A. A. Young, and D. S. Loiselle Effects of BDM, [Ca2+]o, and temperature on the dynamic stiffness of quiescent cardiac trabeculae from rat Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1662 - H1667. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Kirschner, E. Becker, M. Antognozzi, H.-P. Kubis, A. Francino, F. Navarro-Lopez, N. Bit-Avragim, A. Perrot, M. M. Mirrakhimov, K.-J. Osterziel, et al. Hypertrophic cardiomyopathy-related {beta}-myosin mutations cause highly variable calcium sensitivity with functional imbalances among individual muscle cells Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1242 - H1251. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Fukuda, Y. Wu, P. Nair, and H. L. Granzier Phosphorylation of Titin Modulates Passive Stiffness of Cardiac Muscle in a Titin Isoform-dependent Manner J. Gen. Physiol., February 28, 2005; 125(3): 257 - 271. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Olsson, J. R. Patel, D. P. Fitzsimons, J. W. Walker, and R. L. Moss Basal myosin light chain phosphorylation is a determinant of Ca2+ sensitivity of force and activation dependence of the kinetics of myocardial force development Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2712 - H2718. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Murphy Another New Kinase Targets Troponin I Circ. Res., November 26, 2004; 95(11): 1043 - 1045. [Full Text] [PDF] |
||||
![]() |
B. B. Roman, P. H. Goldspink, E. Spaite, D. Urboniene, R. McKinney, D. L. Geenen, R. J. Solaro, and P. M. Buttrick Inhibition of PKC phosphorylation of cTnI improves cardiac performance in vivo Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2089 - H2095. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Takimoto, D. G. Soergel, P. M.L. Janssen, L. B. Stull, D. A. Kass, and A. M. Murphy Frequency- and Afterload-Dependent Cardiac Modulation In Vivo by Troponin I With Constitutively Active Protein Kinase A Phosphorylation Sites Circ. Res., March 5, 2004; 94(4): 496 - 504. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R Pena and B. M Wolska Troponin I phosphorylation plays an important role in the relaxant effect of {beta}-adrenergic stimulation in mouse hearts Cardiovasc Res, March 1, 2004; 61(4): 756 - 763. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |